Novartis Divests Non-Core OTCs, Realigns Consumer Supply Chain
This article was originally published in The Pink Sheet Daily
Novartis sells six OTC brands, including Bufferin, to focus resources on core consumer health products. The firm also is realigning its consumer health supply chain, including restructuring its Lincoln, Nebraska, manufacturing plant, where the workforce will be cut 40%.
You may also be interested in...
The Swiss drug maker filed its IL-17 inhibitor secukinumab in the U.S. and Europe, providing an opportunity to beat rivals Amgen and Eli Lilly to the market with a first-in-class drug. Secukinumab is one of two drugs Novartis filed in the fourth quarter, the firm reported during a year-end earnings call Jan. 29.
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
FDA inspectors were in Novartis Consumer Health’s Lincoln, Neb., plant in December and January, as the company was deciding to halt production and recall products. An inspection report notes 10 observations – eight of them repeats from FDA’s visit in mid-2011.